# Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy

> **NCT05204394** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Viriom** · enrollment: 438 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** VM-1500A-LAI
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT05204394
- **Lead sponsor:** Viriom
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-10-16
- **Target enrollment:** 438 (ESTIMATED)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05204394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05204394, "Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05204394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*